625126-75-2

Upstream product

• 625126-74-1 C₂₁H₃₁NO₄ 
• 75-30-9 2-iodo-propane 
• 625098-78-4 benzyl (1S,3R)-3-[(diphenylmethylene)amino]cyclopentanecarboxylate 
• 765297-57-2 C₁₃H₁₇NO₂*ClH 
• 693245-54-4 (1S,3R)-benzyl-(N-BOC-3-amino)-cyclopentanecarboxylate 
• 134003-04-6 (1R,4S)-4-aminocyclopenten-2-ene-1-carboxylic acid 
• 151907-80-1 (1R,4S)-4-[(tert-butoxycarbonyl)amino]cyclopent-2-ene-1-carboxylic acid 
• 261165-05-3 (1S,3R)-3-(tert-butoxycarbonylamino)cyclopentanecarboxylic acid 

Downstream Products

• 625126-74-1 C₂₁H₃₁NO₄ 
• 625128-83-8 C₂₁H₃₁NO₄ 
• 625098-81-9 C₂₁H₃₁NO₃ 
• 862120-99-8 C₂₂H₃₃NO₃ 
• 625098-82-0 C₂₃H₃₀F₃NO₄ 

Relevant academic research and scientific papers

AMINOCYCLOPENTYL PYRIDOPYRAZINONE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of Formula I and Formula II (wherein A, E, j, k, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, X, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

TETRAHYDROPYRANYL CYCLOPENTYL 1-SUBSTITUTED AND 1,1-DISUBSTITUTED TETRAHYDROISOQUINOLINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of Formula I: I (wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.